Ratings Yield10 Bioscience, Inc.

Equities

YTEN

US98585K8624

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
0.255 ^USD	-6.49%		-17.79%	+6.56%

Apr. 01	Transcript : Yield10 Bioscience, Inc., Q4 2023 Earnings Call, Apr 01, 2024
Apr. 01	Yield10 Bioscience, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
YIELD10 BIOSCIENCE, INC.	+6.56%	4.2M	-
IQVIA HOLDINGS INC.	-1.42%	41.35B	B
LONZA GROUP AG	+42.15%	40.38B	A
MODERNA, INC.	+1.97%	39.05B	B-
CELLTRION, INC.	-14.19%	26.67B	C
ICON PUBLIC LIMITED COMPANY	+1.82%	24.07B	B-
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.36B	B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.68B	C+
MEDPACE HOLDINGS, INC.	+21.36%	11.6B	C+
UNITED THERAPEUTICS CORPORATION	+8.20%	11.15B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes